JP6788592B2 - 血管新生阻害用ｃ−１９ステロイド - Google Patents

血管新生阻害用ｃ−１９ステロイド Download PDF

Info

Publication number
JP6788592B2
JP6788592B2 JP2017535799A JP2017535799A JP6788592B2 JP 6788592 B2 JP6788592 B2 JP 6788592B2 JP 2017535799 A JP2017535799 A JP 2017535799A JP 2017535799 A JP2017535799 A JP 2017535799A JP 6788592 B2 JP6788592 B2 JP 6788592B2
Authority
JP
Japan
Prior art keywords
angiogenesis
cancer
pharmaceutical preparation
administration
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017535799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508474A (ja
JP2018508474A5 (OSRAM
Inventor
ウンターレゲール，ゲルハルト
Original Assignee
クラディス ゲゼルシヤフト ミツト ベシユレンクテル ハフツング
クラディス ゲゼルシヤフト ミツト ベシユレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クラディス ゲゼルシヤフト ミツト ベシユレンクテル ハフツング, クラディス ゲゼルシヤフト ミツト ベシユレンクテル ハフツング filed Critical クラディス ゲゼルシヤフト ミツト ベシユレンクテル ハフツング
Publication of JP2018508474A publication Critical patent/JP2018508474A/ja
Publication of JP2018508474A5 publication Critical patent/JP2018508474A5/ja
Application granted granted Critical
Publication of JP6788592B2 publication Critical patent/JP6788592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017535799A 2014-12-30 2015-12-21 血管新生阻害用ｃ−１９ステロイド Expired - Fee Related JP6788592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14200543.8 2014-12-30
EP14200543.8A EP3040075B1 (en) 2014-12-30 2014-12-30 C-19 steroids for inhibiting neovascularization
PCT/EP2015/080762 WO2016107778A1 (en) 2014-12-30 2015-12-21 C-19 steroids for inhibiting neovascularization

Publications (3)

Publication Number Publication Date
JP2018508474A JP2018508474A (ja) 2018-03-29
JP2018508474A5 JP2018508474A5 (OSRAM) 2019-10-10
JP6788592B2 true JP6788592B2 (ja) 2020-11-25

Family

ID=52146363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535799A Expired - Fee Related JP6788592B2 (ja) 2014-12-30 2015-12-21 血管新生阻害用ｃ−１９ステロイド

Country Status (17)

Country Link
US (1) US10426785B2 (OSRAM)
EP (2) EP3040075B1 (OSRAM)
JP (1) JP6788592B2 (OSRAM)
KR (1) KR102481553B1 (OSRAM)
CN (2) CN107206010B (OSRAM)
CA (1) CA2972324C (OSRAM)
DK (1) DK3040075T3 (OSRAM)
EA (2) EA202190993A3 (OSRAM)
ES (1) ES2651442T3 (OSRAM)
HR (1) HRP20171875T1 (OSRAM)
HU (1) HUE037698T2 (OSRAM)
NO (1) NO3040075T3 (OSRAM)
PL (1) PL3040075T3 (OSRAM)
PT (1) PT3040075T (OSRAM)
RS (1) RS56621B1 (OSRAM)
SI (1) SI3040075T1 (OSRAM)
WO (1) WO2016107778A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632445A1 (en) * 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
CN114149923B (zh) * 2021-11-19 2024-03-08 大连理工大学 内皮细胞-平滑肌细胞共培养的单流道微芯片模型的构建方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
EP1756139A4 (en) * 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
ES2547339T3 (es) * 2007-11-13 2015-10-05 Curadis Gmbh Esteroides C-19 para usos terapéuticos específicos
CN101619089B (zh) * 2009-07-28 2011-07-20 陈大刚 抗肿瘤药物cl168、其合成方法及应用

Also Published As

Publication number Publication date
KR102481553B1 (ko) 2022-12-26
CN107206010B (zh) 2021-12-21
NO3040075T3 (OSRAM) 2018-02-10
KR20170100539A (ko) 2017-09-04
EP3215161A1 (en) 2017-09-13
EA039485B1 (ru) 2022-02-01
EA201791209A1 (ru) 2017-11-30
EA202190993A3 (ru) 2021-10-29
US10426785B2 (en) 2019-10-01
JP2018508474A (ja) 2018-03-29
CA2972324A1 (en) 2016-07-07
CN107206010A (zh) 2017-09-26
PL3040075T3 (pl) 2018-03-30
CA2972324C (en) 2023-09-26
PT3040075T (pt) 2017-12-20
RS56621B1 (sr) 2018-03-30
CN113117089A (zh) 2021-07-16
DK3040075T3 (en) 2017-12-18
EP3040075A1 (en) 2016-07-06
ES2651442T3 (es) 2018-01-26
EA202190993A2 (ru) 2021-08-31
US20170360804A1 (en) 2017-12-21
HUE037698T2 (hu) 2018-09-28
EP3040075B1 (en) 2017-09-13
WO2016107778A1 (en) 2016-07-07
SI3040075T1 (en) 2018-04-30
HRP20171875T1 (hr) 2018-01-26

Similar Documents

Publication Publication Date Title
Koyanagi et al. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities
Wu et al. Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho-Smad2/3 at linker regions in vivo and in vitro
Abramovitch et al. Stimulation of tumour growth by wound-derived growth factors
Deng et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib
Li et al. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway
JP5308160B2 (ja) 前立腺疾病及び皮膚癌におけるイソチオシアネート系化合物の使用
Zhang et al. Inhibition of PI3K/Akt/NF-κB signaling by Aloin for ameliorating the progression of osteoarthritis: in vitro and in vivo studies
TW200932245A (en) Methods and compositions for inhibiting angiogenesis
Wang et al. Colorectal cancer cells establish metabolic reprogramming with cancer-associated fibroblasts (CAFs) through lactate shuttle to enhance invasion, migration, and angiogenesis
Hwang et al. Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis
CN1954825B (zh) 超微通心络中药组合物及其新用途
Feng et al. A novel chrysin thiazole derivative polarizes macrophages to an M1 phenotype via targeting TLR4
Saxena et al. Anti-miRNA therapeutics for uterine fibroids
Calixto-Tlacomulco et al. CETP-derived peptide seq-1, the key component of HB-ATV-8 vaccine prevents stress responses, and promotes downregulation of pro-fibrotic genes in hepatocytes and stellate cells
Li et al. Astragali Radix-Angelicae Sinensis Radix inhibits the activation of vascular adventitial fibroblasts and vascular intimal proliferation by regulating the TGF-β1/Smad2/3 pathway
CN107206010B (zh) 抑制新血管形成的c-19类固醇
Yu et al. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells
Sun et al. Anti-hepatoma effect of homologous delivery of doxorubicin by HepG2 cells
JP2013170168A (ja) 化合物及びその医薬組成物
JP2018508474A5 (OSRAM)
Zeng et al. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis
CN109692332B (zh) Nudt5蛋白作为结直肠癌治疗靶点的应用
EA044482B1 (ru) Комбинация для ингибирования пролиферации эндотелиальных клеток
TW200407119A (en) Methods and compositions to treat conditions associated with neovascularization
Zhao et al. ACAT1 inhibitor Avasimibe suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via CKB/PI3K-AKT signaling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170727

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181213

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200911

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200918

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200923

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201030

R150 Certificate of patent or registration of utility model

Ref document number: 6788592

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees